Global Bipolar Disorder Therapeutic Market Analysis - Global Industry Size, Share, Trends and Forecast, 2018 – 2025

Published - Aug 2018 | Category - Pharma & Healthcare | No. of Pages - 109 | Published By - ARC


Bipolar disorder also known as manic depression refers to abnormal pattern of elevated mood and depression. Common signs of the condition include, maniac episodes, depressive episodes, hypomanic episodes, associated features, comorbid conditions and others. Exact cause of the condition is not known. However, three causes are observed to be closely associated with bipolar disorder which include, environmental conditions, genetic history or neurological abnormality.

Bipolar disorder is managed in three different ways namely, psychological treatment, medicines and alternative medications. Lithium, and ketamine are potential medications for the treatment of the condition. In addition, mood stabilizers such as carbamazepine, valproic acid and lamotrigine are used. Antipsychotics such as Olanzapine is sometimes used in the treatment. Antidepressants such as aripiprazole are also used during the course of treatment. AstraZeneca, AstraZeneca, JnJ Pharmaceticals, Novartis AG, Eli Lilly, Abbott and Otuska Holdngs Co. Ltd. Are some of the players operating in the market.

Market Dynamics

Rising prevalence of bipolar disorder is driving the growth of the market across the world. In addition, government support in creating awareness regarding the conditions and commercially available treatment options is supporting the market growth. Moreover, technological advancement in accurate detection of the condition at an early stage is supporting the market growth. On the other hand, social stigma associated with receiving treatment for mental disorders is challenging the market growth, mainly in developing countries of Asia Pacific and Latin America.


Quick Buy

Latest Publications